The early diagnosis of inflammatory bowel disease (IBD)-associated spondyloarthritis (SpA/IBD) in patients affected by IBD represents a major topic in clinical practice; in particular, to date there are no available serum biomarkers revealing the presence of joint inflammation in these patients. Sclerostin (SOST), an antagonist of the Wnt/β-catenin pathway, and antisclerostin-immunoglobulin G (anti-SOST-IgG) have been recently studied in patients with ankylosing spondylitis (AS) as a putative marker of disease activity.
Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease / Luchetti, M.M., Ciccia, F., Avellini, C., Benfaremo, D., Guggino, G., Farinelli, A., Ciferri, M., Rossini, M., Svegliati, S., Spadoni, T., Bolognini, L., Fava, G., Mosca, P., Gesuita, R., Skrami, E., Triolo, G., Gabrielli, A.. - In: THE JOURNAL OF RHEUMATOLOGY. - ISSN 0315-162X. - STAMPA. - 00:00(2018), p. jrheum.170833. [10.3899/jrheum.170833]
Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease
Luchetti, Michele Maria
Membro del Collaboration Group
;Avellini, Chiara;Benfaremo, Devis;Farinelli, Alessia;Rossini, Matteo;Svegliati, Silvia;Spadoni, Tatiana;Fava, Giammarco;Gesuita, Rosaria;Skrami, Edlira;Gabrielli, Armando
2018-01-01
Abstract
The early diagnosis of inflammatory bowel disease (IBD)-associated spondyloarthritis (SpA/IBD) in patients affected by IBD represents a major topic in clinical practice; in particular, to date there are no available serum biomarkers revealing the presence of joint inflammation in these patients. Sclerostin (SOST), an antagonist of the Wnt/β-catenin pathway, and antisclerostin-immunoglobulin G (anti-SOST-IgG) have been recently studied in patients with ankylosing spondylitis (AS) as a putative marker of disease activity.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
